Curcumin half analog modulates interleukin-6 and tumor necrosis factor-alpha in inflammatory bowel disease.
Pharmacogn Mag. 2015 Oct ;11(Suppl 2):S296-302. PMID: 26664018
Phani Krishna Kondamudi
BACKGROUND: The present study was aimed at examining the effect of dehydrozingerone (DHZ), half analogue of curcumin which is the active constituent of turmeric (Curcuma longa) in the di-nitrochlorobenzene (DNCB) induced model for inflammatory bowel disease (IBD).
MATERIALS AND METHODS: Male Wistar rats (200-220 g) were divided into four groups (n = 6). Chemical induction of IBD was done by sensitizing with 300µL of 20 g/L of DNCB (in acetone) onto the nape of rats for 14 days followed by intra-colonic instillation of 250 µL of DNCB (0.1% DNCB in 50% alcohol) solution on day 15. Rats in Group 1 (normal control) and Group 2 (DNCB control) were treated with vehicle. Rats in Group 3 were treated with DHZ (100 mg/kg, p.o.; 8 days) and Group 4 animals were treated with sulfasalazine (SS) (100 mg/kg, p.o.; 8 days). On 24(th) day, the rats were killed, colon removed and the macroscopic, biochemical, and histopathological evaluations were performed.
RESULTS: The levels of myeloperoxidase, thiobarbituric acid reactive substrate, and nitrite increased significantly (P<0.05) in the DNCB group whereas reduced significantly in the DHZ and SS treated groups. Serum nitrite levels were found to be insignificant between the different groups. Interleukin-6, tumor necrosis factor-alpha level was significantly high in the DNCB group.
CONCLUSION: These findings show that DHZ can be a promising molecule for the treatment of IBD.